- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02151409
Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects
February 8, 2017 updated by: Novo Nordisk A/S
A Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Trial of Anti-C5aR Antibody (NNC 0151-0000-0000) Administered by i.v. Infusion or s.c. Injection in Healthy Subjects.
This trial is conducted in Europe.
The aim of this trial is to develop a complement system targeted monoclonal antibody (mAb) to be used in treatment of subjects with chronic autoimmune diseases.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Groningen, Netherlands, 9728 NZ
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Informed consent obtained before any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
- Body weight (BW) below or equal to 110.0 kg
- Body Mass Index (BMI) 20.0 - 27.0 kg/m^2, both inclusive
- Good state of health: evidenced by medical history, physical examination and results of laboratory examinations
Exclusion Criteria:
- History of known or suspected cardiovascular diseases including: supine systolic blood pressure (BP) above or equal to 140 mmHg or below 90 mm Hg, diastolic BP above oe equal to 90 mm Hg or below 40 mm Hg, heart rate (HR) in supine position above 100 beats/minute or below 45 beats/minute
- Hepatic insufficiency: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above Upper Limit of Normal (ULN) (retesting is permitted within one week if first test is elevated but below 1.5 fold ULN)
- Renal insufficiency: Serum creatinine above ULN
- Positive for humane immunodeficiency virus (HIV) (by test)
- Positive for hepatitis B (HBV) or hepatitis C (HCV) (by test)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
A single dose (SD), administrated i.v.
(intravenous) or s.c.
(subcutaneously).
|
Experimental: NNC 0151-0000-0000 i.v.
Dose escalation trial
|
A single dose (SD), administrated i.v.
(intravenous) at 8 dose levels.
A single dose (SD), administrated s.c.
(subcutaneously) at 7 dose levels
|
Experimental: NNC 0151-0000-0000 s.c.
Dose escalation trial
|
A single dose (SD), administrated i.v.
(intravenous) at 8 dose levels.
A single dose (SD), administrated s.c.
(subcutaneously) at 7 dose levels
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events (AEs)
Time Frame: Week 0-10
|
Week 0-10
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- The first-in-human trial of the humanised monoclonal antibody NNC 0151-0000-0000 blocking the C5a receptor (C5aR). EULAR (European League Against Rheumatism) 2009; Country: Denmark City: Copenhagen
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
May 28, 2014
First Submitted That Met QC Criteria
May 28, 2014
First Posted (Estimate)
May 30, 2014
Study Record Updates
Last Update Posted (Estimate)
February 9, 2017
Last Update Submitted That Met QC Criteria
February 8, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN8209-1940
- 2008-000731-18 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Oral Science International Inc.AdvarraNot yet recruiting
Clinical Trials on NNC 0151-0000-0000
-
Novo Nordisk A/SCompletedInflammation | Rheumatoid ArthritisUnited Kingdom, Romania, Poland, Denmark, Czech Republic, Hungary
-
Novo Nordisk A/SWithdrawnInflammation | Systemic Lupus ErythematosusUnited States
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A | Haemophilia BUnited Kingdom
-
Janssen Research & Development, LLCCompletedInflammation | Crohn's DiseaseBelgium, France, Israel, Hungary, Russian Federation, Poland, Canada, United States
-
Innate PharmaCompletedInflammation | Rheumatoid ArthritisGermany
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia BUnited States, Canada, United Kingdom, France, Malaysia, Brazil, Croatia, Germany, Italy, Japan, Taiwan
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia BUnited States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Russian Federation, Turkey, Japan, South Africa, Romania
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia BUnited States, Netherlands, Germany, Macedonia, The Former Yugoslav Republic of, United Kingdom, Italy, Malaysia, Hungary, Thailand, France, Russian Federation, Turkey, Japan, South Africa, Canada
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia BUnited States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Turkey, Japan, South Africa, Romania
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A | Haemophilia BSpain, Germany, Japan